Abstracts A9 formulation resulted in less erosion from the total brand. In cases where branded utilization is not converted to TR formulation prior to launch of generic competition, such as risperidone and fluoxetine, or TR launch precedes generic launch by less than six months or not at all, such as azythromycin and sertraline, dramatic reduction in total sales brand was observed. In the unique case where branded escitalopram was introduced prior to the generic launch of citalopram, an effect similar to a branded TR launch was observed. CONCLUSIONS: While generic use typically replaces the majority of branded equivalents in a short timeframe, branded products with a timerelease formulation may limit uptake rate of the generic version of the total branded product.
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i3 Innovus, Medford, MA, USA, 2 Rollins School of Public Health, Emory University, Atlanta, GA, USA, 3 Pfizer Inc., Collegeville, PA, USA, 4 Independent Consultant to Wyeth-Asia Pacific, London, UK, 5 Harvard School of Public Health, Boston, MA, USA OBJECTIVES: Historic data suggest that most 1918 influenza pandemic-related deaths were due to pneumococcal disease (PD); preliminary evidence shows a similar pattern for the 2009 H1N1 influenza outbreak. Implementation of 13-valent pneumococcal conjugate vaccine (PCV13) national immunization programs would likely lessen the impact of a pandemic in Asia-Pacific populations that currently have low pneumococcal vaccination rates; our objective was to quantify this impact in Singapore and Hong Kong. METHODS: We used a decision-analytic model to assess the impact of PCV13 infant vaccination on PD incidence and mortality in an influenza pandemic in Singapore and Hong Kong versus no vaccination. The model was estimated from published sources; both direct and indirect (herd) effects against PD were included. Effectiveness of PCV13 was extrapolated from observed US 7-valent PCV (PCV7) data, using assumptions on serotype prevalence in the pre-PCV7 era, and PCV13 protection against the 6 serotypes not in PCV7. Country-specific data were used where available; where unavailable, US data were used. To simulate acceleration of PD transmission in a flu pandemic, we calibrated to 1918 estimates of countryspecific incidence and mortality, adjusting mortality for the advent of antibiotics. PD incidence and mortality, and total PD-related health-care costs were evaluated over a 1-year horizon. Results are reported in local 2008 currency. RESULTS: Preliminary results of the model indicate that in a pandemic of 1918 severity, PCV13 vaccination would prevent 3,300 cases of hospitalized pneumococcal pneumonia and 320 deaths in Singapore, and save SGD1.53 million in health-care costs (net of vaccination). In Hong Kong, PCV13 would prevent 8,200 cases of hospitalized pneumonia (all-cause), and 2,200 pneumonia deaths, respectively; PCV13 would save HKD250 million in medical costs. CONCLUSIONS: In an influenza pandemic affecting the Asia-Pacific region, infant vaccination with PCV13 would likely be highly effective in reducing pandemic-related deaths, PD cases and associated costs.
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CASE1
IMPLEMENTATION OF A NONFORMULARY PRESCRIBING MONITORING SYSTEMS REVEALS OPPORTUNITIES FOR COST SAVINGS IN AN ACADEMIC MEDICAL CENTER
Helmons PJ, Daniels CE University of California San Diego Medical Center, San Diego, CA, USA ORGANIZATION: University of California San Diego Medical Center (UCSDMC) is a 548 bed academic medical center with an average daily census of 368 patients and 23,000 annual discharges. UCSDMC has a large regional footprint as it is the only academic medical center in the region and serves as the regions burn center and high risk obstetrics and neonatal care center. In addition, UCSDMC was the regions first level 1 trauma unit. Consequently, patients are admitted to UCSDMC with a wide variety of medications and insurance coverage. From a medication safety standpoint, outpatient maintenance medication is generally not substituted in our hospital. In addition, patients are discouraged to bring their own medication into the hospital to assure the quality of the medications. These patient population and policy characteristics make formulary management particularly challenging, as this practice results in a constant baseline use of nonformulary outpatient maintenance medications in our inpatient patient population. PROBLEM OR ISSUE ADDRESSED: Detecting trends in nonformulary prescribing is important as increased use of nonformulary medications could indicate an important clinical need of this medication. On the other hand, increased use of nonformulary medications in therapeutic areas with equivalent but less expensive formulary medications, leads to increased costs. We hypothesized that analyzing trends in nonformulary prescribing leads to detection of irrational and more expensive, nonformulary medications and therefore to cost savings. GOALS: To address these issues, we developed a nonformulary medication use monitoring system designed to improve formulary adherence by 50% and detect irrational nonformulary use at an early stage. OUTCOMES ITEMS USED IN THE DECISION: Formulary adherence is defined as the number of nonformulary medication doses billed divided by the total number of doses billed. As an example of irrational prescribing detected by this system, cost savings associated with reversing nonformulary levalbuterol use to formulary albuterol are reported. IMPLEMENTATION STRATEGY: Trends in nonformulary use are monitored using daily, monthly and semi-annual reports.-Daily monitoring is done by the clinical pharmacist. A report that specifies the nonformulary orders per nursing unit is sent to each pharmacist for follow up. The pharmacist evaluates the order for appropriateness and contacts the physician if substitution to a formulary alternative is possible. The intervention is recorded in the pharmacy information system and compliance is monitored by the pharmacoeconomics specialist.-Monthly monitoring is done by the pharmacoeconomics specialist. The results of this monthly analysis are discussed with the Pharmacist-in-Chief and with the Chair of the P&T Committee.-Semi-annual reporting is done by the pharmacoeconomics specialist. Trends in nonformulary prescribing over a six month period are discussed at the P&T meeting. An action plan is approved to address the findings. RESULTS: The first semi-annual nonformulary prescribing report showed a nonformulary use of 0.26% of billed doses. The most frequently prescribed nonformulary medications were: levalbuterol (bronchodilating agent), latanoprost (ocular glaucoma agent), pentosan (bladder relief agent) and Mg-Al plus (magnesium supplement). Based on this initial report and the lack of formulary alternatives, the P&T committee added the latter three agents to the formulary. However, from a cost savings standpoint, the use of levalbuterol at our institution was discouraged as this agent has no known benefits over our formulary agent albuterol. At the time of the report, levalbuterol was almost 4 times more expensive than albuterol. Collaboration with respiratory therapy and pulmonology was sought to educate prescribers and pharmacists about the therapeutic equivalence of albuterol and levalbuterol. After these interventions, the second semi-annual report showed an 80% decrease of nonformulary use to 0.05% of billed doses. Levalbuterol use decreased by 67% from an average of 24 patients per month in the 6 month period before the intervention to 8 patients after the intervention. Levalbuterol expenditure decreased from $7800 to $1421 over the same period and continues to drop, corresponding to an annualized cost avoidance of $8000. LESSONS LEARNED: This case study shows that in an environment where formulary management is challenging, a nonformulary prescribing monitoring system is successful in decreasing nonformulary prescribing and identifying areas of improvement. The large decrease in use of levalbuterol is only one of the successes resulting from this effort. However, by implementing continuous monitoring of nonformulary prescribing we expect to detect and prevent these excesses in the future. We acknowledge that the monetary savings of decreasing levalbuterol use and nonformulary prescribing as a whole is marginal. However, other benefits of a formulary that is better tailored to the institution's needs could include better inventory management, improved medication safety and less interruptions of therapy. This will be the focus of a subsequent study.
CASE2 INVENTING A TIERED FORMULARY BASED ON THE INCREMENTAL COST-EFFECTIVENESS OF DRUGS
Watkins J 1 , Sullivan S 2 , Ramsey S 3 , Wong E 1 , Veenstra D 2 , Burke W 4 , Roy Choudhury S 1 1 Premera Blue Cross, Mountlake Terrace, WA, USA, 2 University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA, 3 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA, 4 University of Washington, Department of Bioethics and Humanities, Seattle, WA, USA ORGANIZATION: Premera Blue Cross PROBLEM OR ISSUE ADDRESSED: Traditional U.S. payer drug selection processes are based on safety, efficacy and drug cost. As premiums continue to rise, many plan sponsors have responded by raising member cost shares on biologics and other high cost pharmaceuticals. This creates affordability barriers for these drugs, regardless of their clinical value, comparative effectiveness or cost-effectiveness. GOALS: Our novel cost-effectiveness driven formulary design seeks to offset the negative impact of such policies on clinical outcomes and quality of care by assigning the drugs that are the most incrementally cost-effective to the lowest formulary tiers. OUTCOMES ITEMS USED IN THE DECISION: Comparative effectiveness and safety (clinical benefits and harms as determined by our existing formulary process) and incremental cost-effectiveness ratios of specific therapies vs. usual care alternatives, based on published cost-effectiveness analyses, manufacturer-submitted cost-effectiveness models and in some cases, models developed internally by plan staff. Cost-effectiveness studies are subjected to a quality review process before being presented to the formulary committee. IMPLEMENTATION STRATEGY: Premera Blue Cross has created a formulary process that assigns each drug to one of four tiers based on a set of flexible cost-effectiveness thresholds. Incremental costeffectiveness, assessed as rigorously as possible, provides a scientific, transparent and defensible means of maintaining lower cost shares for the highest value drugs, regardless of actual prescription cost. In some cases, a drug may fall in more than one tier, based on the patient population and the particular indication for which it is being used. This presentation describes Premera's formulary process, how the thresholds for each tier were established and how drugs and therapeutic classes are reviewed by an external multidisciplinary expert committee, with specific therapeutic drug class outcome examples. This formulary is being offered as part of a new pharmacy benefit product addressing a currently unmet market need. RESULTS: Premera's new formulary process was developed in 2009. This presentation describes the methods used to establish incremental cost-effectiveness thresholds for each formulary tier and the constitution of an external multidisciplinary expert committee to assign specific drugs to tiers. The rationale and tier assignments for specific therapeutic drug classes are presented as examples. LESSONS LEARNED: Despite limitations to the current availability of clinical and economic outcomes from well-designed studies on which to base tiering decisions, it is possible to implement a credible process based on incremental
